Indian Express
Express India
Screen
Loksatta
Express Cricket
Kashmir Live
Biz Publications Sun, 10 Aug 2008
Finance & Business News
FinancialExpress web
Login | Make this your homepage | Feedback
Home Print Edition Latest News Stocks epaperArchives Subscribe Company Info
Latest News
Industry Sectors
AutomobilesCommoditiesHealth & PharmaInfotechInfrastructureInsuranceJobsLifestyleMediaPowerReal EstateRetailTelecomTravel & Tourism
Markets
Companies
Economy
World News
Banking & Finance
Politics
Sports
AP Breaking News
Most Read Articles
Most Emailed Articles
Print Edition
Sections
Front PagePoliticsEdits & ColumnsSelections From The EconomistFE 360FE InsightInternationalEconomy
Corporates & Markets
Supplement
India InceFEFE InvestorEconomic Survey 07-08BrandWagon
Leaving on a Jet Plane
Defence Expo 2008
FE Centres
FE Columnists
Cartoon Gallery
Budget Ace-Terms
Services
* Matrimonials
* Register FREE on Naukri.com.
* Send Rakhi Gifts To India
* Rs.250 cashback for credit cards*
* Yatra Offers- 10% cash back on Master Card
* Airtel Call Home
* Send Raksha Bandhan Gifts
Channels
* Astrology
* Shopping
* Tenders
* Express Classifieds
* ExpressQnA
* Express Estates
* Express Money
* Express Travel
Group Websites
* Expressindia
* Indian Express
* Screen
* City Newslines
* Express Cricket
* Loksatta
* Express Computer
Events
FE Events
Round Table ConferenceFe Best Banks 2008
Group Events
RNG Excellence in Journalism Award
FE Home - Story
Exchange trade currency futures by month end
Economy Bureau
Posted online: Wednesday, August 06, 2008 at 22:17 hrs
Updated On: Wednesday, August 06, 2008 at 22:17 hrs
Font Size
Print
Feedback
Email
Discuss
Save & Share Article What's this?
Digg My Yahoo Fark
del.icio.us Newsvine Reddit
Rate This Article
1 2 3 4 5 6 7 8 9 10
Rating: 0
The Securities & Exchange Board of India (Sebi) will launch a pilot alternative payment system for public issues by August-end, which would allow investors to keep the application money in their bank accounts till they are allotted shares.
"Hopefully by August end, we will start the pilot project," Sebi chairman CB Bhave told reporters at a seminar organised by the Financial Planning Standards Board India.
NOTE: BHAVE IS A RESPECTED PERSONALITY IN SEBI.
Further, the markets regulator is expected to launch the exchange trade currency futures by this month-end. So far three entities—NSE, MCX-promoter Financial Technologies and a consortium of HDFC, Kotak and SBI —have evinced interest in starting these products.
The pilot payment system would enable investors to earn interest income on their application money till the time of allotment, while sparing them from the hassles of getting refunds in case they are not allotted shares.
Bhave said the current system of payment through cheques and the alternate system would co-exist. Commenting on the pilot system, he said, "We really don't know how the system works. We need to get used to it. We have to sort out glitches if there are any in the beginning."
The alternate payment system, called additional mode of payment through applications supported by blocked amount, will exempt retail investors from making full advance fees. Instead, it would let them retain the in bank accounts till the completion of allotment. The system is dependent on 'Self Certified Syndicate Banks' (SCSB) that would accept the application of retail investors. Banks that wish to offer the ASBA facility must submit a certificate to Sebi for inclusion of its name in the SCSB list. Under the scheme, the SCSBs will block funds to the extent of the bid amount, upload the details in the electronic bidding system and then unblock funds of finalisation of allotment.
This mode of payment will apply only to public issues offered under the book building route and only those retail investors would be part of this payment process who bid at the cut-off price as the single option and agree not to revise their bids.
On exchange traded currency futures, Sebi chairman said that three entities have applied for launching these products. When asked about the specific timeframe for the launch of currency futures, Bhave said this was not in the regulator's hands as the three entities are in various stages of preparing software and setting up hardware for the...
Single Page Format 1 - 2 - Next
Trade Commodities Futures
Futures Trading on 18 Exchanges.Sign Up Now for Free Membership! Your Free Forex Course
Learn How to Trade like a Pro!Get Your Free Course & Start Today. Trade Currency Exchange
Join Easy-Forex: Online 24x7 Trade,$100 Start, 1:200 Leverage, No Fees
Ads by Google
Post Comments
Comments: (Limit 3,000 characters)
Name
Message
Email ID
Subject
TERMS OF USE:
The views represented here are not neccesarily endorsed by www.financialexpress.com and its allied websites. All messages will be moderated and no message that has inflammatory, abusive, derogatory language or any language deemed unfit for publication by the editor will be displayed. Though it will be endeavoured that as many messages as possible be displayed, there will be time lag between the submission and publication of the messages. The website reserves the right to publish or reject any message.
I agree to the terms of use.
Comments
» Exchage traded Currency
Posted by Shyam.P.Kunte on 2008-08-06 09:26:54.130376+05:30
Another exchange is getting born here for speculators mostly of FIIs/Foreign Banks/Corporates to defraud gullible small investors.How come SEBI has forgotten the current MTM losses fiasco and really it is surprising.In a Trade deficit country like ours and with huge unwanted Forex reserves it will spell disaster in long term.May god save our Nation from those tricky financial gambling products.JaiHind
Reply Forward Report Abuse
Most Read Articles
* Implementation cell for Sixth Pay Commission report set up
* Raja pulls up BSNL on slow growth
* BSE board meets amid differences
* Career crossroads: The dilemma of a transfer
More
Shaadi Matrimonials
Get Marriage Proposals by Email EVERYDAY!Register FREE on Naukri.com.
200000+ Hot Job Openings!Send Rakhi Gifts To India
Click here!Yatra Offers
10% cash back on Master Card Send Raksha Bandhan
Gifts and RakhisExpress Classifieds
Post and view free classifieds adExpress Astrology
Know what's in the stars for you
Most Emailed
* Retailers turn to co-op movement for better supply chain management
* Cement, telecom, capital goods to post higher growth: study
* AP mulls unified municipal Act
* Ailing sugar co-ops in AP get Rs 270 cr from Centre
More
Home Print Edition Latest News Stocks epapersArchives Subscribe Company Info
FinancialExpress web
About Us | Contact Us | Advertisers | Site Map | Make us your homepage | Work for Us | RSS | Subscribe | Electronic Edition | Privacy Policy
© 2008: Indian Express Newspapers (Mumbai) Ltd. All rights reserved throughout the world
Monday, August 11, 2008
DISCLOSURE OF SHAREHOLDINGS IN ACCORDANCE WITH STOCK MARKET RULES
More
BigChartsVirtual Stock ExchangeFiLife.comWSJ AsiaWSJ EuropeWSJ AmericasWSJ ChineseFinancial News OnlineSEARCH
Choose a quote match or "go" to get quote
Choose a topic to search news:
close
Welcome, please sign in.
My Portfolio • Community • VSE • Alerts
Front PageNews & Commentary
Markets
Mutual Funds & ETFs
Personal Finance
Technology
Tools & Research
My MarketWatch
Community
Video
News & Commentary
Columnists First Take Special ReportsHow to Buy
Trading Strategies
The Heat is On
Hong Kong
The Short Sellers
Beijing Olympics 2008
A Growing Hunger
Dubai
Blogs Podcasts Industry NewsTechnology
Health Care
Retail
Automobiles
Economy & PoliticsFed
The Election
NewslettersGuru's Corner
Directory
Hulbert Financial Digest
Election 2008
latest news [HTZ] Hertz Q2 revenue $2.28 bln vs $2.18 bln
Disclosure of Shareholdings in Accordance with Stock Market Rules
Last update: 12:16 p.m. EDT Aug. 7, 2008
GENEVA, SWITZERLAND, Aug 07, 2008 (MARKET WIRE via COMTEX) -- Addex Pharmaceuticals (SWISS: ADXN) announced today that on August 6, 2008, Varuma AG, Aeschenvorstadt 55, 4051 Basel, Switzerland, has informed of exceeding the threshold of 3% in the shareholding of Addex Pharmaceuticals Ltd., holding a total of 231,425 registered shares, corresponding to 3.95% of the voting rights. The beneficiary of the shareholdings of Varuma AG is Mr. Rudolf Maag, at Neuhofweg 11, 4102 Binningen, Switzerland.
NOTE: ADDEX IS A WELL KNOWN PHARMACEUTICAL COMPANY.
About Addex
Addex Pharmaceuticals discovers and develops allosteric modulators for human health. Allosteric modulators are an emerging class of orally available small molecule therapeutic agents that we believe will offer patients better results than classical drugs. Most marketed drugs bind receptors where the body's own natural molecular activators (i.e. endogenous ligands) bind, specifically to a key part of each receptor's anatomy called the "active site". In short, most drugs must out-compete endogenous ligands for the active site. By contrast, allosteric modulators are non-competitive because they bind receptors and modify their function even if the endogenous ligand also is binding it. In addition, because of this, allosteric modulators aren't limited to simply turning a receptor on or off, the way most drugs are. Instead, they act more like a dimmer switch, offering control over the degree of activation or deactivation, while offering the body the ability to maintain control over initiating receptor activation. Furthermore, the allosteric approach generally affords freedom to operate - even on well-known, clinically validated targets - because the intellectual property surrounding allosteric chemistry and the allosteric sites on receptors is most often un-exploited.
ADX10059, our most advanced product, is an mGluR5 NAM (metabotropic glutamate receptor 5 negative allosteric modulator). It has demonstrated clinically and statistically significant efficacy in separate Phase IIa clinical trials in gastroesophageal reflux disease (GERD) patients and migraine headache patients and has potential in additional indications.
The Addex allosteric modulation discovery and development platform have been additionally validated through three seperatate product license or collaboration agreements with Merck & Co., Inc. and Johnson & Johnson as well as investments by Roche Ventures and SR One, the venture investment arm of GlaxoSmithKline. Contacts
Disclaimer
The foregoing release contains forward-looking statements that can be identified by terminology such as "not approvable", "continue", "believes", "believe", "will", "remained open to exploring", "would", "could", or similar expressions, or by express or implied discussions regarding Addex Pharmaceuticals Ltd, its business, the potential approval of its products by regulatory authorities, or regarding potential future revenues from such products. Such forward- looking statements reflect the current views of Addex Pharmaceuticals Ltd regarding future events, and involve known and unknown risks, uncertainties and other factors that may cause actual results with allosteric modulators of mGluR4, mGluR2, mGluR5 or other therapeutic targets to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no guarantee that allosteric modulators of mGluR4, mGluR2 or mGluR5 will be approved for sale in any market or by any regulatory authority. Nor can there be any guarantee that allosteric modulators of mGluR4, mGluR2, mGluR5 or other therapeutic targets will achieve any particular levels of revenue (if any) in the future. In particular, management's expectations regarding allosteric modulators of mGluR4, mGluR2, mGluR5 or other therapeutic targets could be affected by, among other things, unexpected actions by our partners, unexpected regulatory actions or delays or government regulation generally; unexpected clinical trial results, including unexpected new clinical data and unexpected additional analysis of existing clinical data; competition in general; government, industry and general public pricing pressures; the company's ability to obtain or maintain patent or other proprietary intellectual property protection. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated, believed, estimated or expected. Addex Pharmaceuticals is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.
Copyright Copyright Hugin AS 2008. All rights reserved.
Chris Maggos
Head of IR & Communications
Addex Pharmaceuticals
+41 22 884 15 11
Email Contact
SOURCE: Addex Pharmaceuticals
http://www2.marketwire.com/mw/emailprcntct?id=07E63FA2DB9FD852
Copyright 2008 Market Wire, All rights reserved.
Top stories
21 minutes ago Shanghai stocks drop ahead of Olympics ceremony
10:30 PM 8/7/08 Rackspace prices IPO at $12.50 a share
2:37 PM 8/7/08 General obligation bonds have edge over other tax-free munis
Real Estate Weekly E-newsletter Real estate news and commentary from our Personal Finance staff every week.
Sign up
Privacy policy
Most Popular
READE-MAILEDEDITOR'S PICK
Long-time Bear Granville turns bullish
U.S. stocks end steeply down as financials shake up market
U.S. workers must unite to protect their 401(k) savings
Supply and demand turned upside down as commodities plunge
U.S. stock futures drops on AIG loss, Wal-Mart view
Oil futures end losing streak on pipeline shutdown
AIG shares drop by record 18% after 'horrific' results
CORRECT: Pending home sales index rises 5.3% in June: NAR
Citi to settle charges on auction-rate securities
Media's self-censorship over Edwards is bigger scandal
Why McCain would be a mediocre president
U.S. workers must unite to protect their 401(k) savings
Supply and demand turned upside down as commodities plunge
Media's self-censorship over Edwards is bigger scandal
CORRECT: Pending home sales index rises 5.3% in June: NAR
Long-time Bear Granville turns bullish
Citi to settle charges on auction-rate securities
Global coal demand is swelling and these companies will benefit
AIG shares drop by record 18% after 'horrific' results
Decoding the latest business buzzwords
Shanghai stocks drop ahead of Olympics ceremony
Rackspace prices IPO at $12.50 a share
General obligation bonds have edge over other tax-free munis
Why McCain would be a mediocre president
Cathay Pacific posts loss on high fuel prices
Get the Latest MarketWatch News >>
PARTNER CENTER
Site Index | Topics | Archive | Help | Feedback | Media Archive | Premium Products | Mobile | RSS | Podcasts | Company Info | Advertising Media Kit | DJ Client Solutions
The Wall Street Journal Digital Network:
WSJ.com | Barron's Online | BigCharts | Virtual Stock Exchange | All Things Digital | MarketWatch Community
RealEstateJournal.com | Financial News Online | WSJ.com Small Business
Copyright © 2008 MarketWatch, Inc. All rights reserved.
By using this site, you agree to the Terms of Service and Privacy Policy . Disclosure of Shareholdings in Accordance with Stock Market Rules - MarketWatchIntraday data provided by Interactive Data Real Time Services, a division of Interactive Data Corp. and subject to terms of use. Historical and current end-of-day data provided by Interactive Data Pricing and Reference Data. More information on NASDAQ traded symbols and their current financial status. Intraday data delayed 15 minutes for Nasdaq, and 20 minutes for other exchanges. Dow Jones Indexes(SM) from Dow Jones & Company, Inc. SEHK intraday data is provided by Comstock and is at least 60-minutes delayed. All quotes are in local exchange time. Real-time last sale data provided by NASDAQ.
BigChartsVirtual Stock ExchangeFiLife.comWSJ AsiaWSJ EuropeWSJ AmericasWSJ ChineseFinancial News OnlineSEARCH
Choose a quote match or "go" to get quote
Choose a topic to search news:
close
Welcome, please sign in.
My Portfolio • Community • VSE • Alerts
Front PageNews & Commentary
Markets
Mutual Funds & ETFs
Personal Finance
Technology
Tools & Research
My MarketWatch
Community
Video
News & Commentary
Columnists First Take Special ReportsHow to Buy
Trading Strategies
The Heat is On
Hong Kong
The Short Sellers
Beijing Olympics 2008
A Growing Hunger
Dubai
Blogs Podcasts Industry NewsTechnology
Health Care
Retail
Automobiles
Economy & PoliticsFed
The Election
NewslettersGuru's Corner
Directory
Hulbert Financial Digest
Election 2008
latest news [HTZ] Hertz Q2 revenue $2.28 bln vs $2.18 bln
Disclosure of Shareholdings in Accordance with Stock Market Rules
Last update: 12:16 p.m. EDT Aug. 7, 2008
GENEVA, SWITZERLAND, Aug 07, 2008 (MARKET WIRE via COMTEX) -- Addex Pharmaceuticals (SWISS: ADXN) announced today that on August 6, 2008, Varuma AG, Aeschenvorstadt 55, 4051 Basel, Switzerland, has informed of exceeding the threshold of 3% in the shareholding of Addex Pharmaceuticals Ltd., holding a total of 231,425 registered shares, corresponding to 3.95% of the voting rights. The beneficiary of the shareholdings of Varuma AG is Mr. Rudolf Maag, at Neuhofweg 11, 4102 Binningen, Switzerland.
NOTE: ADDEX IS A WELL KNOWN PHARMACEUTICAL COMPANY.
About Addex
Addex Pharmaceuticals discovers and develops allosteric modulators for human health. Allosteric modulators are an emerging class of orally available small molecule therapeutic agents that we believe will offer patients better results than classical drugs. Most marketed drugs bind receptors where the body's own natural molecular activators (i.e. endogenous ligands) bind, specifically to a key part of each receptor's anatomy called the "active site". In short, most drugs must out-compete endogenous ligands for the active site. By contrast, allosteric modulators are non-competitive because they bind receptors and modify their function even if the endogenous ligand also is binding it. In addition, because of this, allosteric modulators aren't limited to simply turning a receptor on or off, the way most drugs are. Instead, they act more like a dimmer switch, offering control over the degree of activation or deactivation, while offering the body the ability to maintain control over initiating receptor activation. Furthermore, the allosteric approach generally affords freedom to operate - even on well-known, clinically validated targets - because the intellectual property surrounding allosteric chemistry and the allosteric sites on receptors is most often un-exploited.
ADX10059, our most advanced product, is an mGluR5 NAM (metabotropic glutamate receptor 5 negative allosteric modulator). It has demonstrated clinically and statistically significant efficacy in separate Phase IIa clinical trials in gastroesophageal reflux disease (GERD) patients and migraine headache patients and has potential in additional indications.
The Addex allosteric modulation discovery and development platform have been additionally validated through three seperatate product license or collaboration agreements with Merck & Co., Inc. and Johnson & Johnson as well as investments by Roche Ventures and SR One, the venture investment arm of GlaxoSmithKline. Contacts
Disclaimer
The foregoing release contains forward-looking statements that can be identified by terminology such as "not approvable", "continue", "believes", "believe", "will", "remained open to exploring", "would", "could", or similar expressions, or by express or implied discussions regarding Addex Pharmaceuticals Ltd, its business, the potential approval of its products by regulatory authorities, or regarding potential future revenues from such products. Such forward- looking statements reflect the current views of Addex Pharmaceuticals Ltd regarding future events, and involve known and unknown risks, uncertainties and other factors that may cause actual results with allosteric modulators of mGluR4, mGluR2, mGluR5 or other therapeutic targets to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no guarantee that allosteric modulators of mGluR4, mGluR2 or mGluR5 will be approved for sale in any market or by any regulatory authority. Nor can there be any guarantee that allosteric modulators of mGluR4, mGluR2, mGluR5 or other therapeutic targets will achieve any particular levels of revenue (if any) in the future. In particular, management's expectations regarding allosteric modulators of mGluR4, mGluR2, mGluR5 or other therapeutic targets could be affected by, among other things, unexpected actions by our partners, unexpected regulatory actions or delays or government regulation generally; unexpected clinical trial results, including unexpected new clinical data and unexpected additional analysis of existing clinical data; competition in general; government, industry and general public pricing pressures; the company's ability to obtain or maintain patent or other proprietary intellectual property protection. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated, believed, estimated or expected. Addex Pharmaceuticals is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.
Copyright Copyright Hugin AS 2008. All rights reserved.
Chris Maggos
Head of IR & Communications
Addex Pharmaceuticals
+41 22 884 15 11
Email Contact
SOURCE: Addex Pharmaceuticals
http://www2.marketwire.com/mw/emailprcntct?id=07E63FA2DB9FD852
Copyright 2008 Market Wire, All rights reserved.
Top stories
21 minutes ago Shanghai stocks drop ahead of Olympics ceremony
10:30 PM 8/7/08 Rackspace prices IPO at $12.50 a share
2:37 PM 8/7/08 General obligation bonds have edge over other tax-free munis
Real Estate Weekly E-newsletter Real estate news and commentary from our Personal Finance staff every week.
Sign up
Privacy policy
Most Popular
READE-MAILEDEDITOR'S PICK
Long-time Bear Granville turns bullish
U.S. stocks end steeply down as financials shake up market
U.S. workers must unite to protect their 401(k) savings
Supply and demand turned upside down as commodities plunge
U.S. stock futures drops on AIG loss, Wal-Mart view
Oil futures end losing streak on pipeline shutdown
AIG shares drop by record 18% after 'horrific' results
CORRECT: Pending home sales index rises 5.3% in June: NAR
Citi to settle charges on auction-rate securities
Media's self-censorship over Edwards is bigger scandal
Why McCain would be a mediocre president
U.S. workers must unite to protect their 401(k) savings
Supply and demand turned upside down as commodities plunge
Media's self-censorship over Edwards is bigger scandal
CORRECT: Pending home sales index rises 5.3% in June: NAR
Long-time Bear Granville turns bullish
Citi to settle charges on auction-rate securities
Global coal demand is swelling and these companies will benefit
AIG shares drop by record 18% after 'horrific' results
Decoding the latest business buzzwords
Shanghai stocks drop ahead of Olympics ceremony
Rackspace prices IPO at $12.50 a share
General obligation bonds have edge over other tax-free munis
Why McCain would be a mediocre president
Cathay Pacific posts loss on high fuel prices
Get the Latest MarketWatch News >>
PARTNER CENTER
Site Index | Topics | Archive | Help | Feedback | Media Archive | Premium Products | Mobile | RSS | Podcasts | Company Info | Advertising Media Kit | DJ Client Solutions
The Wall Street Journal Digital Network:
WSJ.com | Barron's Online | BigCharts | Virtual Stock Exchange | All Things Digital | MarketWatch Community
RealEstateJournal.com | Financial News Online | WSJ.com Small Business
Copyright © 2008 MarketWatch, Inc. All rights reserved.
By using this site, you agree to the Terms of Service and Privacy Policy . Disclosure of Shareholdings in Accordance with Stock Market Rules - MarketWatchIntraday data provided by Interactive Data Real Time Services, a division of Interactive Data Corp. and subject to terms of use. Historical and current end-of-day data provided by Interactive Data Pricing and Reference Data. More information on NASDAQ traded symbols and their current financial status. Intraday data delayed 15 minutes for Nasdaq, and 20 minutes for other exchanges. Dow Jones Indexes(SM) from Dow Jones & Company, Inc. SEHK intraday data is provided by Comstock and is at least 60-minutes delayed. All quotes are in local exchange time. Real-time last sale data provided by NASDAQ.
Subscribe to:
Posts (Atom)